ProMetic Life Sciences Inc. (PLI) Given Consensus Recommendation of “Buy” by Brokerages
Shares of ProMetic Life Sciences Inc. (TSE:PLI) have been given an average recommendation of “Buy” by the five research firms that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is C$3.60.
PLI has been the subject of a number of analyst reports. National Bank Financial boosted their price objective on ProMetic Life Sciences from C$2.00 to C$2.50 in a research report on Wednesday, August 30th. Royal Bank Of Canada lowered their price objective on ProMetic Life Sciences from C$4.00 to C$3.50 and set an “outperform” rating for the company in a research report on Wednesday, August 16th. Finally, TD Securities decreased their target price on ProMetic Life Sciences from C$4.50 to C$3.50 and set a “speculative buy” rating for the company in a research note on Wednesday, August 16th.
In other ProMetic Life Sciences news, insider Patrick Sartore sold 64,579 shares of the company’s stock in a transaction on Thursday, August 24th. The stock was sold at an average price of C$1.15, for a total value of C$74,265.85. Also, Director Dwun-Hou Chen sold 32,321 shares of the company’s stock in a transaction on Thursday, August 24th. The shares were sold at an average price of C$1.14, for a total value of C$36,845.94. In the last quarter, insiders acquired 184,150 shares of company stock valued at $231,429 and sold 388,397 shares valued at $507,577.
ProMetic Life Sciences (TSE PLI) traded down C$0.04 during midday trading on Monday, reaching C$1.35. The company’s stock had a trading volume of 522,343 shares, compared to its average volume of 1,035,265. ProMetic Life Sciences has a 52 week low of C$1.12 and a 52 week high of C$2.92.
About ProMetic Life Sciences
Prometic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.
Receive News & Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.